All In Biotech

Drug Trial Radar · NCT04803201

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 170 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

170

Planned (sponsor's estimate)

Start

Oct 8, 2021

Primary completion

May 19, 2027

Study completion May 19, 2027

Sponsor

Lead sponsor
Alliance for Clinical Trials in OncologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Mar 17, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help find out if this approach is better or worse than the usual approach for treating peripheral T-cell lymphoma.

Conditions

  • Angioimmunoblastic T-cell Lymphoma
  • Enteropathy-Associated T-Cell Lymphoma
  • Follicular T-Cell Lymphoma
  • Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
  • Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma
  • Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
  • Peripheral T-Cell Lymphoma, Not Otherwise Specified

Interventions

  • CyclophosphamideDrug

    Given IV

  • DoxorubicinDrug

    Given IV

  • VincristineDrug

    Given IV

  • PrednisoneDrug

    Given PO

  • EtoposideDrug

    Given IV or PO

  • DuvelisibDrug

    Given PO

  • Oral azacitidineDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete remission (CR) rateTime frame: Up to 6 months

Locations

96 sites in 1 country. Site status is shown where the registry gives one.

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas · Recruiting

  • City of Hope Comprehensive Cancer Center

    Duarte, California · Active not recruiting

  • UC San Diego Moores Cancer Center

    La Jolla, California · Active not recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia · Active not recruiting

  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach

    Deerfield Beach, Florida · Recruiting

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    Miami, Florida · Recruiting

  • Grady Health System

    Atlanta, Georgia · Recruiting

  • Emory University Hospital Midtown

    Atlanta, Georgia · Recruiting

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • Emory Saint Joseph's Hospital

    Atlanta, Georgia · Recruiting

  • Augusta University Medical Center

    Augusta, Georgia · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • University of Illinois

    Chicago, Illinois · Recruiting

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois · Completed

  • Northwestern Medicine Cancer Center Kishwaukee

    DeKalb, Illinois · Recruiting

  • Northwestern Medicine Cancer Center Delnor

    Geneva, Illinois · Recruiting

  • Northwestern Medicine Lake Forest Hospital

    Lake Forest, Illinois · Recruiting

  • AMG Libertyville - Oncology

    Libertyville, Illinois · Suspended

  • Memorial Hospital East

    Shiloh, Illinois · Recruiting

  • Carle Cancer Center

    Urbana, Illinois · Recruiting

  • Northwestern Medicine Cancer Center Warrenville

    Warrenville, Illinois · Recruiting

  • UI Health Care Mission Cancer and Blood - Ankeny Clinic

    Ankeny, Iowa · Recruiting

  • Iowa Methodist Medical Center

    Des Moines, Iowa · Recruiting

  • UI Health Care Mission Cancer and Blood - Des Moines Clinic

    Des Moines, Iowa · Recruiting

  • UI Health Care Mission Cancer and Blood - Laurel Clinic

    Des Moines, Iowa · Recruiting

  • University of Iowa/Holden Comprehensive Cancer Center

    Iowa City, Iowa · Recruiting

  • UI Health Care Mission Cancer and Blood - Waukee Clinic

    Waukee, Iowa · Recruiting

  • University of Kansas Cancer Center-Overland Park

    Overland Park, Kansas · Recruiting

  • University of Kansas Hospital-Westwood Cancer Center

    Westwood, Kansas · Recruiting

  • University of Kentucky/Markey Cancer Center

    Lexington, Kentucky · Recruiting

  • Our Lady of the Lake Physician Group

    Baton Rouge, Louisiana · Recruiting

  • University of Maryland/Greenebaum Cancer Center

    Baltimore, Maryland · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Trinity Health IHA Medical Group Hematology Oncology - Brighton

    Brighton, Michigan · Recruiting

  • Essentia Health Cancer Center

    Duluth, Minnesota · Recruiting

  • Mayo Clinic in Rochester

    Rochester, Minnesota · Recruiting

  • Saint Luke's Hospital

    Chesterfield, Missouri · Recruiting

  • Siteman Cancer Center at West County Hospital

    Creve Coeur, Missouri · Recruiting

  • Mercy Hospital Springfield

    Springfield, Missouri · Suspended

Showing 40 of 96 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.